Financials Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

Equities

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
24.16 ^CNY	-1.39%		-1.39%	+7.33%

Apr. 25	Sunshine Guojian Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 21	Sunshine Guojian Pharmaceutical's Profit Surges Sixfold in 2023	MT

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	15,190	11,431	7,833	13,884	14,902	-	-
Enterprise Value (EV) ¹	15,190	11,431	7,833	13,884	14,902	14,902	14,902
P/E ratio	-70.4 x	618 x	159 x	46.9 x	48.3 x	50.3 x	42 x
Yield	-	-	-	-	-	-	-
Capitalization / Revenue	23.2 x	12.3 x	9.49 x	13.7 x	11.9 x	11.1 x	9.59 x
EV / Revenue	23.2 x	12.3 x	9.49 x	13.7 x	11.9 x	11.1 x	9.59 x
EV / EBITDA	-227 x	175 x	49.2 x	33.5 x	43.6 x	37.8 x	34.4 x
EV / FCF	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-
Price to Book	3.36 x	2.52 x	1.7 x	2.84 x	2.86 x	2.71 x	2.54 x
Nbr of stocks (in thousands)	616,211	616,211	616,786	616,786	616,786	-	-
Reference price ²	24.65	18.55	12.70	22.51	24.16	24.16	24.16
Announcement Date	2/26/21	2/25/22	3/21/23	2/23/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	655	928.8	825.5	1,014	1,253	1,343	1,554
EBITDA ¹	-67.05	65.39	159.4	414.3	342	394.4	432.7
EBIT ¹	-188.8	-43.63	36.94	318.2	329.2	316.8	378.6
Operating Margin	-28.82%	-4.7%	4.48%	31.38%	26.27%	23.59%	24.36%
Earnings before Tax (EBT) ¹	-264.1	-53.39	28.96	310.6	321.4	309	370.8
Net income ¹	-200.3	18.06	49.3	294.6	307.5	296.7	355.2
Net margin	-30.57%	1.94%	5.97%	29.05%	24.54%	22.09%	22.85%
EPS ²	-0.3500	0.0300	0.0800	0.4800	0.5000	0.4800	0.5750
Free Cash Flow	-	-	-	-	-	-	-
FCF margin	-	-	-	-	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-
Dividend per Share	-	-	-	-	-	-	-
Announcement Date	2/26/21	2/25/22	3/21/23	2/23/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-
Free Cash Flow	-	-	-	-	-	-	-
ROE (net income / shareholders' equity)	-5.54%	0.4%	1.08%	6.2%	5.93%	5.34%	6.04%
ROA (Net income/ Total Assets)	-	-	-	-	-	-	-
Assets ¹	-	-	-	-	-	-	-
Book Value Per Share ²	7.340	7.370	7.470	7.940	8.440	8.920	9.500
Cash Flow per Share ²	-0.0700	-0.4100	0.3800	0.6800	-0.0400	0.2900	0.3300
Capex ¹	227	264	221	135	69.5	53.3	72.1
Capex / Sales	34.65%	28.4%	26.76%	13.34%	5.55%	3.97%	4.64%
Announcement Date	2/26/21	2/25/22	3/21/23	2/23/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.16 CNY

Average target price

32.43 CNY

Spread / Average Target

+34.23%

	1st Jan change	Capi.
SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD	+7.33%	2.06B
CSL LIMITED	-0.07%	91.42B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	41.08B
BIOGEN INC.	-9.06%	34.26B
UCB	+55.32%	25.27B
BIOMARIN PHARMACEUTICAL INC.	-16.61%	15.27B
INCYTE CORPORATION	-9.14%	12.81B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.11%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.61%	11.42B
SWEDISH ORPHAN BIOVITRUM AB	+7.79%	9.16B